These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21121926)

  • 1. New insights in gene-derived therapy: the example of Duchenne muscular dystrophy.
    Aartsma-Rus A; den Dunnen JT; van Ommen GJ
    Ann N Y Acad Sci; 2010 Dec; 1214():199-212. PubMed ID: 21121926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exon skipping with morpholino oligomers: new treatment option for cardiomyopathy in Duchenne muscular dystrophy?
    Bauer R; Katus HA; Müller OJ
    Cardiovasc Res; 2010 Feb; 85(3):409-10. PubMed ID: 20008475
    [No Abstract]   [Full Text] [Related]  

  • 6. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for Duchenne muscular dystrophy.
    Verhaart IE; Aartsma-Rus A
    Curr Opin Neurol; 2012 Oct; 25(5):588-96. PubMed ID: 22892952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y; Takeda S
    Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental therapy in Duchenne muscular dystrophy].
    van den Bergen JC; Straathof CS; Aartsma-Rus A; Ginjaar IB; Verschuuren JJ
    Ned Tijdschr Geneeskd; 2009 May; 153(18):870-5. PubMed ID: 19475867
    [No Abstract]   [Full Text] [Related]  

  • 11. [An opening in Duchenne muscular dystrophy: persistent therapeutic rescue of dystrophin by vectorized antisense mediated exon skipping in mdx mice].
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Med Sci (Paris); 2004 Dec; 20(12):1163-5. PubMed ID: 15581476
    [No Abstract]   [Full Text] [Related]  

  • 12. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular therapy for duchenne muscular dystrophy].
    Takeshima Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():626-31. PubMed ID: 16416864
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frontline studies on Duchenne muscular dystrophy treatment].
    Matsuo M
    No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
    Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
    Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.
    Malik V; Rodino-Klapac LR; Viollet L; Wall C; King W; Al-Dahhak R; Lewis S; Shilling CJ; Kota J; Serrano-Munuera C; Hayes J; Mahan JD; Campbell KJ; Banwell B; Dasouki M; Watts V; Sivakumar K; Bien-Willner R; Flanigan KM; Sahenk Z; Barohn RJ; Walker CM; Mendell JR
    Ann Neurol; 2010 Jun; 67(6):771-80. PubMed ID: 20517938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
    Hoffman EP; Bronson A; Levin AA; Takeda S; Yokota T; Baudy AR; Connor EM
    Am J Pathol; 2011 Jul; 179(1):12-22. PubMed ID: 21703390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.